Cleerly ISCHEMIA vs ClearRead CT

ClearRead CT emphasizes seamless PACS integration and vendor-neutral processing, allowing radiologists to remain within their native reading environment, which is a significant workflow advantage. User testimonials confirm easy installation and integration, contributing to faster reading times without requiring additional workstations or logins. Cleerly ISCHEMIA offers a web-based platform with interactive reports, which is user-friendly, but ClearRead CT's deep integration into existing radiology workflows provides a more streamlined experience for its target users.

Cleerly ISCHEMIA provides a comprehensive, prognostic assessment of coronary artery disease by non-invasively determining ischemia likelihood at a vessel level, estimating FFR, and characterizing coronary plaque. It has been validated in multiple clinical trials, demonstrating higher diagnostic accuracy and prognostic utility for major adverse cardiovascular events (MACE) compared to other non-invasive methods. While ClearRead CT offers significant value in pulmonary nodule detection and CAC scoring, Cleerly's detailed, prognostic insights into CAD can more directly guide definitive treatment decisions and has a Category I CPT code for reimbursement.

Neither tool provides transparent pricing, making a direct cost comparison impossible. However, Cleerly ISCHEMIA has secured a Category I CPTu00ae code (75580) for its non-invasive FFR estimation, which signifies established reimbursement pathways and a clearer financial value proposition for providers. This established reimbursement mechanism significantly de-risks the financial investment for healthcare institutions. ClearRead CT does not publicly list similar Category I CPT codes for its primary features.

ClearRead CT demonstrates strong enterprise readiness through its flexible deployment options (on-premise and cloud), vendor-neutral PACS integration, and extensive adoption in over 100 VA sites and globally in 20+ countries. It is also ISO27001 certified and supports role-based authentication. While Cleerly ISCHEMIA is HIPAA compliant and FDA-cleared with API integration, ClearRead CT's proven large-scale deployment across diverse enterprise environments and explicit security certifications suggest a broader and more robust readiness for complex healthcare systems.

Cleerly ISCHEMIA's innovation lies in its ability to non-invasively estimate fractional flow reserve (FFR) and provide comprehensive, prognostic characterization of coronary plaque from a standard CCTA scan. This '3-in-1' approach for atherosclerosis, stenosis, and ischemia, with its prognostic value for MACE, represents a significant advancement in guiding cardiac care and potentially reducing the need for invasive procedures. While ClearRead CT's patented vessel suppression and automated nodule tracking are innovative for pulmonary imaging, Cleerly's holistic and prognostic approach to CAD diagnosis offers a more transformative impact on patient management.

Riverain Technologies provides a comprehensive support framework for ClearRead CT, including dedicated customer care via email and phone with specified hours, a support ticket system, FAQs, system requirements, workflow guides, and manuals. This detailed offering of resources and direct contact options indicates a robust and accessible support structure. Cleerly also states a commitment to customer success and offers various resources, but ClearRead CT's explicit breakdown of support services appears more extensive.